Key points from article :
Novartis sought to see whether giving low doses of everolimus to people over 65 increased their response to flu vaccines.
Called the “first human aging trial” as it looked at whether the immune system of elderly people could be made to act younger.
Startup resTORbio is licensing two drug molecules for aging-related disease.
Will further test whether such drugs can rejuvenate aged immune cells.
Everolimus is a derivative of rapamycin – which makes mice live 25% longer.
